The discovery of novel chemotypes of p38 kinase inhibitors

被引:43
作者
Diller, DJ
Lin, TH
Metzger, A
机构
[1] Pharmacopeia Inc, Mol Modeling, Princeton, NJ 08543 USA
[2] Pharmacopeia Inc, Biol, Princeton, NJ 08543 USA
[3] Pharmacopeia Inc, Chem, Princeton, NJ 08543 USA
关键词
D O I
10.2174/1568026054985948
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the late 1970s and the early 1980s the initial p38 chemotype, the triaryl imidazoles, was discovered as an off-target effect during the development of cyclooxygenase and 5-lipoxygenase inhibitors long before the identity of the p38 kinase was known. During the last 10 years a number of novel p38 chemotypes were discovered via high throughput screening. More recently, the first series of p38 inhibitors discovered by xray crystallographic and virtual screening was announced. Finally, throughout the life span of p38 drug discovery programs significant medicinal chemistry effort has continually been placed on the design of new inhibitors from known chernotypes using molecular modeling, protein crystallography, hybrid design and simply sound intuition. Indeed, the search for p38 kinase inhibitors offers an excellent historical perspective as to how technological changes that have taken place in the pharmaceutical industry over the last decade, have affected the ways in which new leads are discovered and advanced. It is the intent of this review to highlight the discoveries of novel p38 chemotypes, emphasizing where possible the key technologies used in the discoveries and the knowledge gained from each discovery.
引用
收藏
页码:953 / 965
页数:13
相关论文
共 86 条
[1]   Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity [J].
Adams, JL ;
Boehm, JC ;
Gallagher, TF ;
Kassis, S ;
Webb, EF ;
Hall, R ;
Sorenson, M ;
Garigipati, R ;
Griswold, DE ;
Lee, JC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (21) :2867-2870
[2]   Pyrimidinylimidazole inhibitors of CSBP/P37 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes [J].
Adams, JL ;
Boehm, JC ;
Kassis, S ;
Gorycki, PD ;
Webb, EF ;
Hall, R ;
Sorenson, M ;
Lee, JC ;
Ayrton, A ;
Griswold, DE ;
Gallagher, TF .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (22) :3111-3116
[3]   Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 Redistribution® screen [J].
Almholt, DLC ;
Loechel, F ;
Nielsen, SJ ;
Krog-Jensen, C ;
Terry, R ;
Bjorn, SP ;
Pedersen, HC ;
Præstegaard, M ;
Moller, S ;
Heide, M ;
Pagliaro, L ;
Mason, AJ ;
Butcher, S ;
Dahl, SW .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2004, 2 (01) :7-20
[4]  
Behr Thomas M, 2003, Curr Opin Investig Drugs, V4, P1059
[5]  
BENDER PE, 1979, Patent No. 4175127
[6]   1-substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency [J].
Boehm, JC ;
Smietana, JM ;
Sorenson, ME ;
Garigipati, RS ;
Gallagher, TF ;
Sheldrake, PL ;
Bradbeer, J ;
Badger, AM ;
Laydon, JT ;
Lee, JC ;
Hillegass, LM ;
Griswold, DE ;
Breton, JJ ;
ChabotFletcher, MC ;
Adams, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3929-3937
[7]   New inhibitors of p38 kinase [J].
Boehm, JC ;
Adams, JL .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (01) :25-37
[8]   Phenoxypyrimidine inhibitors of p38α kinase:: Synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-2-phenoxypyrimidin-4-yl) imidazoles [J].
Boehm, JC ;
Bower, MJ ;
Gallagher, TF ;
Kassis, S ;
Johnson, SR ;
Adams, JL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (09) :1123-1126
[9]   A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis [J].
Brown, DS ;
Belfield, AJ ;
Brown, GR ;
Campbell, D ;
Foubister, A ;
Masters, DJ ;
Pike, KG ;
Snelson, WL ;
Wells, SL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (21) :5383-5387
[10]   Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5) [J].
Callahan, JF ;
Burgess, JL ;
Fornwald, JA ;
Gaster, LM ;
Harling, JD ;
Harrington, FP ;
Heer, J ;
Kwon, C ;
Lehr, R ;
Mathur, A ;
Olson, BA ;
Weinstock, J ;
Laping, NJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (05) :999-1001